RESUMEN
Adherence challenges with oral pre-exposure prophylaxis have stimulated interest in alternate modes of administration including long-acting injections. We conducted 30 in-depth interviews with 26 male trial participants and 4 clinical providers in a Phase IIa study (ÉCLAIR) evaluating the use of long-acting cabotegravir (CAB-LA) injections in New York and San Francisco. Interviews exploring attitudes and experiences with CAB-LA were audiotaped, transcribed, and analyzed using thematic content analysis. Despite a high frequency of some level of side effects, almost all participants reported being interested in continuing with CAB-LA, versus a daily oral, due to its convenience and the perceived advantage of not worrying about adhering to pills. Providers reinforced the importance of CAB-LA as a prevention option and the need for guidelines to assist patient decision-making. Further research is needed on the acceptability of CAB-LA among men and women at higher risk for HIV in different settings.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/prevención & control , Profilaxis Pre-Exposición , Piridonas/uso terapéutico , Adulto , Ensayos Clínicos como Asunto , Estudios Transversales , Toma de Decisiones , Femenino , Humanos , Entrevistas como Asunto , Masculino , Persona de Mediana Edad , New York , Investigación Cualitativa , San Francisco , Grabación en Cinta , Estados Unidos , Adulto JovenRESUMEN
Replication-competent HIV-1 can be isolated from infected patients despite prolonged plasma virus suppression by anti-retroviral treatment. Recent studies have identified resting, memory CD4+ T lymphocytes as a long-lived latent reservoir of HIV-1 (refs. 4,5). Cross-sectional analyses indicate that the reservoir is rather small, between 103 and 107 cells per patient. In individuals whose plasma viremia levels are well suppressed by anti-retroviral therapy, peripheral blood mononuclear cells containing replication-competent HIV-1 were found to decay with a mean half-life of approximately 6 months, close to the decay characteristics of memory lymphocytes in humans and monkeys. In contrast, little decay was found in a less-selective patient population. We undertook this study to address this apparent discrepancy. Using a quantitative micro-culture assay, we demonstrate here that the latent reservoir decays with a mean half-life of 6.3 months in patients who consistently maintain plasma HIV-1 RNA levels of fewer than 50 copies/ml. Slower decay rates occur in individuals who experience intermittent episodes of plasma viremia. Our findings indicate that the persistence of the latent reservoir of HIV-1 despite prolonged treatment is due not only to its slow intrinsic decay characteristics but also to the inability of current drug regimens to completely block HIV-1 replication.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/fisiología , Latencia del Virus , Replicación Viral , Adulto , Células Cultivadas , Estudios Transversales , Infecciones por VIH/inmunología , VIH-1/genética , VIH-1/aislamiento & purificación , Homosexualidad Masculina , Humanos , Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Lesiones por Pinchazo de Aguja , ARN Viral/sangre , Factores de Tiempo , Carga ViralRESUMEN
Analysis of the HIV protease gene from the plasma of HIV-infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir. Mutants at valine-82, although insufficient to confer resistance, appeared first in most patients. Significant phenotypic resistance required multiple mutations in HIV protease, which emerged subsequently in an ordered, stepwise fashion. The appearance of resistance mutations was delayed in patients with higher plasma levels of ritonavir. Early mutants retained susceptibility to structurally diverse protease inhibitors, suggesting that dual protease inhibitor therapy might increase the duration of viral suppression.
Asunto(s)
Inhibidores de la Proteasa del VIH/farmacología , Proteasa del VIH/genética , VIH/efectos de los fármacos , Mutación , Tiazoles/farmacología , Valina/análogos & derivados , Codón , Genotipo , VIH/enzimología , VIH/genética , Infecciones por VIH/sangre , Humanos , Fenotipo , Ritonavir , Valina/genética , Valina/farmacologíaRESUMEN
The mechanism of CD4(+) T cell depletion in human immunodeficiency virus (HIV)-1 infection remains controversial. Using deuterated glucose to label the DNA of proliferating cells in vivo, we studied T cell dynamics in four normal subjects and seven HIV-1-infected patients naive to antiretroviral drugs. The results were analyzed using a newly developed mathematical model to determine fractional rates of lymphocyte proliferation and death. In CD4(+) T cells, mean proliferation and death rates were elevated by 6.3- and 2.9-fold, respectively, in infected patients compared with normal controls. In CD8(+) T cells, the mean proliferation rate was 7.7-fold higher in HIV-1 infection, but the mean death rate was not significantly increased. Five of the infected patients underwent subsequent deuterated glucose labeling studies after initiating antiretroviral therapy. The lymphocyte proliferation and death rates in both CD4(+) and CD8(+) cell populations were substantially reduced by 5-11 weeks and nearly normal by one year. Taken together, these new findings strongly indicate that CD4(+) lymphocyte depletion seen in AIDS is primarily a consequence of increased cellular destruction, not decreased cellular production.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , Adulto , Apoptosis/inmunología , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/citología , Linfocitos T CD8-positivos/citología , División Celular , Femenino , Expresión Génica , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Estado de Salud , Humanos , Etiquetado Corte-Fin in Situ , Antígeno Ki-67/genética , Antígeno Ki-67/inmunología , Cinética , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Monocitos/citología , Factores de Tiempo , Carga ViralRESUMEN
We studied how combination antiviral therapy affects B cell abnormalities associated with HIV-1 infection, namely elevated circulating immunoglobulin (Ig)G antibody-secreting cell (ASC) frequencies and hypergammaglobulinemia. Within a few weeks of starting antiviral therapy, there is a marked decline in IgG-ASC frequency in both acutely and chronically infected people, whereas the hypergammaglobulinemia often present during chronic infection is more gradually resolved. These reductions are sustained while HIV-1 replication is suppressed. HIV-1 antigen-specific B cell responses are also affected by therapy, manifested by a rapid decline in circulating gp120-specific ASCs. Anti-gp120 titers slowly decrease in chronically infected individuals and usually fail to mature in acutely infected individuals who were promptly treated with antiretroviral therapy. Long-term nonprogressors have high titer antibody responses to HIV-1 antigens, but no detectable gp120-specific IgG-ASC, and normal (or subnormal) levels of total circulating IgG-ASC. Overall, we conclude that HIV-1 infection drives B cell hyperactivity, and that this polyclonal activation is rapidly responsive to decreases in viral replication caused by combination antiviral therapy.
Asunto(s)
Antivirales/uso terapéutico , Linfocitos B/inmunología , Anticuerpos Anti-VIH/inmunología , Antígenos VIH/inmunología , Infecciones por VIH/inmunología , VIH-1/aislamiento & purificación , Antivirales/farmacología , Quimioterapia Combinada , Infecciones por VIH/tratamiento farmacológico , HumanosRESUMEN
The role of the thymus in HIV-1 pathogenesis remains unclear. We developed an assay to quantify the number of recent thymic emigrants in blood based on the detection of a major excisional DNA byproduct (termed alpha1 circle) of T cell receptor rearrangement. By studying 532 normal individuals, we found that alpha1 circle numbers in blood remain high for the first 10-15 yr of life, a sharp drop is seen in the late teen years, and a gradual decline occurs thereafter. Compared with age-matched uninfected control individuals, alpha1 circle numbers in HIV-1-infected adults were significantly reduced; however, there were many individuals with normal alpha1 circle numbers. In 74 individuals receiving highly active antiretroviral therapy, we found no appreciable effect on alpha1 circle numbers in those whose baseline values were already within the normal range, but significant increases were observed in those with a preexisting impairment. The increases in alpha1 circle numbers were, however, numerically insufficient to account for the rise in levels of naive T lymphocytes. Overall, it is difficult to invoke thymic regenerative failure as a generalized mechanism for CD4 lymphocyte depletion in HIV-1 infection, as alpha1 circle numbers are normal in a substantial subset of HIV-1-infected individuals.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , VIH-1 , Linfocitos T/inmunología , Adolescente , Adulto , Envejecimiento/sangre , Envejecimiento/genética , Envejecimiento/inmunología , Fármacos Anti-VIH/uso terapéutico , Secuencia de Bases , Estudios de Casos y Controles , Movimiento Celular , Niño , Cartilla de ADN/genética , ADN Circular/sangre , ADN Circular/genética , Reordenamiento Génico de Linfocito T , Infecciones por VIH/genética , Humanos , Reacción en Cadena de la Polimerasa , Linfocitos T/metabolismoRESUMEN
Circadian rhythms of ionized calcium and phosphate concentrations have been demonstrated in human blood. A computer-derived model curve representing the 24-hour fluctuations in ionized calcium cannot be correlated consistently with curves for total calcium or phosphate. Knowledge of these circadian rhythms provides a physiological basis for further understanding the interactions between blood minerals and calcium-regulating hormones.
Asunto(s)
Calcio/sangre , Ritmo Circadiano , Fosfatos/sangre , Adulto , Humanos , MasculinoRESUMEN
A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t 1/2 = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t 1/2 = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time--defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles--is 2.6 days. These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.
Asunto(s)
Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/virología , Infecciones por VIH/virología , VIH-1/fisiología , Virión/fisiología , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Recuento de Linfocito CD4 , Supervivencia Celular , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/administración & dosificación , Inhibidores de la Proteasa del VIH/uso terapéutico , VIH-1/efectos de los fármacos , Semivida , Humanos , Cinética , Modelos Biológicos , ARN Viral/sangre , Análisis de Regresión , Ritonavir , Tiazoles/administración & dosificación , Tiazoles/uso terapéutico , Valina/administración & dosificación , Valina/análogos & derivados , Valina/uso terapéutico , Viremia , Virión/efectos de los fármacos , Replicación ViralRESUMEN
Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.
Asunto(s)
Infecciones por VIH/inmunología , Infecciones por VIH/virología , VIH-1/fisiología , Recuento de Linfocitos/métodos , ARN Viral/sangre , Linfocitos T Citotóxicos/inmunología , Fármacos Anti-VIH/uso terapéutico , Recuento de Linfocito CD4 , Colorantes , Efecto Citopatogénico Viral , Citotoxicidad Inmunológica , Citometría de Flujo , Productos del Gen gag , Productos del Gen pol , Infecciones por VIH/tratamiento farmacológico , VIH-1/genética , Antígenos HLA-A , Humanos , Oligopéptidos , Sensibilidad y Especificidad , Carga Viral , ViremiaRESUMEN
The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Linfocitos T CD4-Positivos/virología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/fisiología , Latencia del Virus , Replicación Viral , Fármacos Anti-VIH/farmacología , Linfocitos T CD4-Positivos/inmunología , Separación Celular , Estudios Transversales , Farmacorresistencia Microbiana/genética , Quimioterapia Combinada , VIH-1/efectos de los fármacos , VIH-1/genética , VIH-1/aislamiento & purificación , Humanos , Memoria Inmunológica , Activación de Linfocitos , Mutación , Provirus/fisiología , ARN Viral/sangre , Factores de Tiempo , Carga Viral , Viremia , Integración ViralRESUMEN
The effects of surface imprinting on the adsorption and desorption properties of benzene- and diethylbenzene-bridged periodic mesoporous organosilicas (PMOs) acting as GC stationary-phase preconcentration sorbents for benzene and xylene were examined. Surface-imprinted and nonimprinted PMOs with diethylbenzene (DEB), benzene (BENZ), and ethane (BTSE) bridges and nonimprinted mesoporous silica (MCM-41) were prepared via well-established surfactant templating synthetic methods. The imprinted materials were synthesized using a surfactant demonstrated to produce trinitrotoluene (TNT) selective sorbents with increased adsorption capacity for cresol and 4-nitrophenol as well as TNT. Powder XRD and nitrogen sorption measurements revealed that all of the materials were mesoporous with the DEB materials having a random pore structure and lower surface area than the other materials which had ordered pore structures. Results for maximum uptake of benzene and p-xylene indicate a small but consistent positive effect on the adsorption of benzene and p-xylene due to surface imprinting. Comparing the surface area normalized uptakes (mg/m(2)) for materials having the same organic bridge with and without imprinting (DEB vs TDMI-DEB and BENZ vs TDMI-BENZ) shows that in seven of eight comparisons the imprinted analogue had a higher aromatic uptake. The imprinted samples showed higher weight normalized uptakes (mg/g) in five of eight cases. When used as a GC stationary phase, the organosilica materials yield more symmetrical chromatographic peaks and better separation than MCM-41, indicating superior trapping of BTX analytes, particularly at low concentrations. Additionally, these materials rapidly desorb the preconcentrated compounds.
RESUMEN
Despite prolonged treatment with highly active antiretroviral therapy (HAART), infectious HIV-1 continues to replicate and to reside latently in resting memory CD4(+) T lymphocytes, creating a major obstacle to HIV-1 eradication. It is therefore not surprising to observe a prompt viral rebound after discontinuation of HAART. The nature of the rebounding virus, however, remains undefined. We now report on the genetic characterization of rebounding viruses in eight patients in whom plasma viremia was undetectable throughout about 3 years of HAART. Taking advantage of the extensive length polymorphism in HIV-1 env, we found that in five patients who did not show HIV-1 replication during treatment, the rebound virus was identical to those isolated from the latent reservoir. In three other patients, two of whom had been free of plasma viremia but had showed some residual viral replication, the rebound virus was genetically different from the latent reservoir virus, corresponding instead to minor viral variants detected during the course of treatment in lymphoid tissues. We conclude that in cases with apparent complete HIV-1 suppression by HAART, viral rebound after cessation of therapy could have originated from the activation of virus from the latent reservoir. In patients with incomplete suppression by chemotherapy, however, the viral rebound is likely triggered by ongoing, low-level replication of HIV-1, perhaps occurring in lymphoid tissues.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Genes env , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/genética , Polimorfismo de Longitud del Fragmento de Restricción , Adulto , Recuento de Linfocito CD4 , Humanos , Tejido Linfoide/virología , Masculino , ARN Viral/aislamiento & purificación , Recurrencia , Carga Viral , Latencia del VirusRESUMEN
Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/inmunología , Fármacos Anti-VIH/uso terapéutico , VIH-1/inmunología , Replicación Viral , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/virología , Adulto , Proteína p24 del Núcleo del VIH/inmunología , Humanos , Masculino , Persona de Mediana Edad , Linfocitos T Citotóxicos/inmunología , Viremia/tratamiento farmacológico , Viremia/inmunologíaRESUMEN
Peripheral resting mononuclear leukocytes were compared for their capacities to repair DNA lesions induced by a 1-hour exposure to a standardized 10-microM dose of N-acetoxy-N-2-fluorenylacetamide (N-AcO-2-FAA). Leukocytes from the following 3 groups were studied: 39 control subjects, 40 patients after colonic resection because of colorectal cancer (disease-free at the time of this study), and 28 individuals with a hereditary predisposition to colorectal cancer. Although the level of N-AcO-2-FAA that bound to mononuclear leukocyte DNA was the same for the various population groups, the level of N-AcO-2-FAA-induced unscheduled DNA synthesis (UDS) was significantly reduced in the mononuclear leukocytes of individuals who had had colorectal cancer or a genetic predisposition for the disease. These findings indicate that a deficiency in mononuclear leukocyte DNA repair synthesis is associated with the development of colorectal cancer in these populations. Our observation of this nonspecific UDS deficiency (relating to colorectal cancer) was not explained by experimental variations among the sampled groups with regard to individual differences in lymphocyte heterogeneity, age, sex, smoking habits, or blood pressure.
Asunto(s)
Adenocarcinoma/genética , Neoplasias del Colon/genética , Reparación del ADN , Neoplasias del Recto/genética , Acetoxiacetilaminofluoreno/farmacología , Adulto , Anciano , Susceptibilidad a Enfermedades , Femenino , Humanos , Leucocitos/efectos de los fármacos , Leucocitos/ultraestructura , Masculino , Persona de Mediana Edad , LinajeRESUMEN
The mononuclear leukocytes from peripheral blood samples of individuals with (n = 30) and without (n = 48) colonic polyps were examined for their abilities to carry out unscheduled DNA synthesis (UDS) induced by N-acetoxy-N-2-fluorenylacetamide (N-AcO-2-FAA). Individuals with polyps had significantly reduced UDS values compared to the nonpolyp group (P less than 0.01). Furthermore, in a more comprehensive study, patients with hyperplastic polyps had N-AcO-2-FAA-induced UDS values not significantly different from control individuals who were asymptomatic and free from colonic disease as judged by complete colonoscopy. However, patients who had had adenomatous polyps in their large bowel had significantly reduced levels of N-AcO-2-FAA-induced UDS in their mononuclear leukocytes (P less than 0.005). When N-AcO-2-FAA binding to DNA determinations were made in parallel and DNA repair proficiency indices were calculated (i.e., N-AcO-2-FAA-induced UDS/N-AcO-2-FAA binding to DNA), the patients with adenomatous polyps were still shown to be deficient in carrying out DNA repair synthesis. Since adenomatous polyps of the large bowel are considered the premalignant lesion for colorectal cancer, we postulate that reduced UDS may be a genetically sensitive marker that is useful in studying the mechanisms of genetic predisposition to colorectal cancer.
Asunto(s)
Pólipos del Colon/metabolismo , Reparación del ADN , ADN/biosíntesis , Pólipos Intestinales/metabolismo , Leucocitos/metabolismo , Neoplasias del Recto/metabolismo , Acetoxiacetilaminofluoreno , Adenoma/metabolismo , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Human mononuclear leukocytes were exposed to prooxidants such as H2O2, phorbol-12-myristate-13-acetate, and 4-nitroquinoline-N-oxide, and the effects on induction of DNA damage and repair were evaluated. ADP ribosylation was activated by prooxidant exposure and the response was bimodal with peaks of activation occurring at about 30 min and 4-5 h. Other evidence for prooxidant-induced DNA damage was provided by nucleoid sedimentation assays. Unscheduled DNA synthesis (UDS) was only slightly induced by prooxidant exposure which suggested that either the DNA lesions were repaired by a short patch mechanism involving little UDS, or the repair process was inhibited by prooxidant exposures, or some combination of both. This point was clarified by the fact that the repair of DNA lesions induced by N-acetoxy-2-acetylaminofluorene, an inducer of large patch DNA repair, was inhibited in a dose-dependent manner by exposure to H2O2 and the inhibition was dependent on ADP ribosylation. In contrast, the repair of DNA strand breaks induced by prooxidant exposures as identified above were complete within about 8 h and the repair was independent of ADP ribosylation. Both ADP ribosylation and N-acetoxy-2-acetylaminofluorene-induced UDS were shown to be up- and down-regulated by the redox state of human mononuclear leukocytes indicating a unique mechanism of cellular control over DNA repair.
Asunto(s)
2-Acetilaminofluoreno , 4-Nitroquinolina-1-Óxido/farmacología , Acetoxiacetilaminofluoreno/farmacología , Daño del ADN , Reparación del ADN , Peróxido de Hidrógeno/farmacología , Leucocitos/metabolismo , Nitroquinolinas/farmacología , Acetato de Tetradecanoilforbol/farmacología , Antígenos de Diferenciación de Linfocitos T/análisis , ADN/sangre , ADN/efectos de los fármacos , Replicación del ADN/efectos de los fármacos , Humanos , Técnicas In Vitro , Cinética , Leucocitos/efectos de los fármacos , Oxidación-Reducción , Poli(ADP-Ribosa) Polimerasas/sangreRESUMEN
OBJECTIVE: To evaluate the safety and antiretroviral activity of ritonavir (Norvir) and saquinavir (Invirase) combination therapy in patients with HIV infection. DESIGN: A multicenter, randomized, open-label clinical trial. SETTING: Seven HIV research units in the USA and Canada. PATIENTS: A group of 141 adults with HIV infection, CD4 T lymphocyte counts of 100-500 x 10(6) cells/l, whether treated previously or not with reverse transcriptase inhibitor therapy, but without previous HIV protease inhibitor drug therapy. INTERVENTIONS: After discontinuation of prior therapy for 2 weeks, group I patients were randomized to receive either combination (A) ritonavir 400 mg and saquinavir 400 mg twice daily or (B) ritonavir 600 mg and saquinavir 400 mg twice daily. After an initial safety assessment of group I patients, group II patients were randomized to receive either (C) ritonavir 400 mg and saquinavir 400 mg three times daily or (D) ritonavir 600 mg and saquinavir 600 mg twice daily. Investigators were allowed to add up to two reverse transcriptase inhibitors (including at least one with which the patient had not been previously treated) to a patient's regimen after week 12 for failure to achieve or maintain an HIV RNA level < or = 200 copies/ml documented on two consecutive occasions. MEASUREMENTS: Plasma HIV RNA levels and CD4+ T-lymphocyte counts were measured at baseline, every 2 weeks for 2 months, and monthly thereafter. Safety was assessed through the reporting of adverse events, physical examinations, and the monitoring of routine laboratory tests. RESULTS: The 48 weeks of study treatment was completed by 75% (106/141) of the patients. Over 80% of the patients on treatment at week 48 had an HIV RNA level < or = 200 copies/ml. In addition, intent-to-treat and on-treatment analyses revealed comparable results. Suppression of plasma HIV RNA levels was similar for all treatment arms (mean areas under the curve minus baseline through 48 weeks were-1.9, -2.0, -1.6, -1.8 log10 copies/ml in ritonavir-saquinavir 400-400 mg twice daily, 600-400 mg twice daily, 400-400 mg three times daily, and 600-600 mg twice daily, respectively). Median CD4 T-lymphocyte count rose by 128 x 10(6) cells/l from baseline, with an interquartile range (IQR) of 82-221 x 10(6) cells/l. The most common adverse events were diarrhea, circumoral paresthesia, asthenia, and nausea. Reversible elevation of serum transaminases (> 5 x upper limit of normal) occurred in 10% (14/141) of the patients enrolled in this study and was associated with baseline abnormalities in liver function tests, baseline hepatitis B surface antigen positivity, or hepatitis C antibody positivity (relative risk, 5.0; 95% confidence interval 1.5-16.9). Most moderate or severe elevations in liver function tests occurred in patients treated with ritonavir-saquinavir 600-600 mg twice daily. CONCLUSIONS: Ritonavir 400 mg combined with saquinavir 400 mg twice daily with the selective addition of reverse transcriptase inhibitors was the best-tolerated regimen of four dose-ranging regimens and was equally as active as the higher dose combinations in HIV-positive patients without previous protease inhibitor treatment.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/uso terapéutico , VIH-1 , Ritonavir/uso terapéutico , Saquinavir/uso terapéutico , Adulto , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/farmacocinética , Seguridad de Productos para el Consumidor , Quimioterapia Combinada , Femenino , Infecciones por VIH/líquido cefalorraquídeo , Infecciones por VIH/mortalidad , Infecciones por VIH/virología , Inhibidores de la Proteasa del VIH/efectos adversos , Inhibidores de la Proteasa del VIH/farmacocinética , VIH-1/genética , Humanos , Masculino , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Ritonavir/efectos adversos , Ritonavir/farmacocinética , Saquinavir/efectos adversos , Saquinavir/farmacocinéticaRESUMEN
6 beta-Hydroxycortisol (6 beta OHF) is a highly polar metabolite of cortisol, probably formed in the endoplasmic reticulum of hepatocytes by cytochrome P-450-dependent microsomal monoxygenases. Lead decreases the activity of cytochrome P-450-dependent microsomal hydroxylases in vivo and in vitro. To examine possible inhibitory effects of lead on 6 beta OHF metabolism, urinary 6 beta OHF excretion was measured in 26 children with mild to moderate increases in blood lead concentrations. Children were divided into 2 groups on the basis of their response to the EDTA provocative test. This test was used to assess the size of chelatable and potentially toxic lead stores in such children. Children with elevated urinary lead excretion after an EDTA provocative test, i.e. elevated tissue lead stores, had markedly decreased urinary excretion of 6 beta OHF (178 +/- 15 micrograms/m2 X 24 h) compared to children who had negative tests (333 +/- 40 micrograms/m2 X 24 h; P less than 0.01); their urinary cortisol excretion was not different from that of age-matched controls. These findings suggest that lead, at relatively low concentrations, may interfere with hepatic microsomal formation of a cortisol metabolite.
Asunto(s)
Hidrocortisona/análogos & derivados , Intoxicación por Plomo/metabolismo , Microsomas Hepáticos/enzimología , Niño , Preescolar , Sistema Enzimático del Citocromo P-450/metabolismo , Ácido Edético , Femenino , Humanos , Hidrocortisona/orina , Plomo/metabolismo , Intoxicación por Plomo/tratamiento farmacológico , Intoxicación por Plomo/enzimología , MasculinoRESUMEN
Osteocalcin, the vitamin K-dependent protein synthesized in bone, is found in blood. The level of circulating osteocalcin has recently been used as an indicator of the rate of bone turnover. We measured serum osteocalcin during 24-h periods in 6 normal 20- to 30-yr-old men and 4 women. Blood was sampled via an indwelling venous catheter every 30 or 60 min for 24 h. Circadian rhythmicity in circulating osteocalcin was found in 9 of the 10 individuals studied. Osteocalcin levels fell during the morning, rose in the afternoon and early evening, and reached a peak nocturnally. There were no consistent correlations between osteocalcin concentrations and circulating levels of ionized calcium, total calcium, or inorganic phosphate in the subjects tested. This study illustrates the importance of regulating the time of blood sampling for osteocalcin determinations in clinical investigations of metabolic bone disease.
Asunto(s)
Proteínas de Unión al Calcio/sangre , Minerales/sangre , Adulto , Calcio/sangre , Ritmo Circadiano , Femenino , Fase Folicular , Humanos , Fase Luteínica , Masculino , Osteocalcina , Fosfatos/sangre , Factores de TiempoRESUMEN
Ten hormone-deficient hypoparathyroid children have been successfully treated with orally administered 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] within a dose range of 0.01--0.10 microgram/kg . day for a total of 35 patient yr. Resistance to 1,25-(OH)2D3 therapy was not observed. By monitoring the blood ionized calcium level (normal range, 4.05--5.14 mg/dl) at monthly intervals, 8 hypercalcemic and 10 hypocalcemic episodes were recognized during the entire treatment experience, though the patients were asymptomatic. In the former cases, cessation of treatment for 3 days resulted in normocalcemia; in the latter, half of the episodes were transient and related to intercurrent febrile illnesses. The remaining hypocalcemic occurrences responded to an increase in the dosage of 1,25-(OH)2D3. During 1,25-(OH)2D3 treatment, the mean ionized calcium level for individual patients ranged from 4.04--4.39 mg/dl. Urinary Ca excretion, expressed as a ratio of calcium to creatinine, ranged from 0.177--0.244. Twenty-four-hour mean levels of serum 1,25-(OH)2D did not correlate with the blood ionized calcium concentration in 4 patients who underwent sequential blood sampling every 1--2 h for a total of 59 time points (r = 0.05; P greater tha 0.10). To elucidate the temporal relationship between hormonal and mineral responses to exogenous PTH, we administered bovine PTH to four untreated hypoparathyroid children. Serum concentrations of PTH increased before the rise in ionized calcium, which in turn preceded the elevation in circulating 1,25-(OH)2D. This order was followed also in the fall in serum concentrations of these blood constituents to pre-PTH infusion values. These results indicate responsiveness of the l alpha-hydroxylase enzyme to exogenous PTH in hormone-deficient hypoparathyroid children.